Zobrazeno 1 - 4
of 4
pro vyhledávání: '"W S, Harkonen"'
Publikováno v:
International journal of dermatology. 38(8)
A new topical formulation of betamethasone valerate (BMV) with enhanced dermal penetration has been developed.These studies were designed to evaluate: (1) the relative bioavailability of BMV foam, and (2) the safety and efficacy of BMV foam in the tr
Publikováno v:
Molecular biotherapy. 2(3)
We conducted a study to determine if treatment with cyclophosphamide (CY) could suppress the formation of anti-murine and anti-ricin A chain antibodies in rats treated with a murine monoclonal antibody-ricin A chain immunotoxin (IT). Female Sprague-D
Autor:
D A, Baker, W S, Harkonen
Publikováno v:
Targeted diagnosis and therapy. 3
Monoclonal antibody-based therapeutic products are subject to the same regulatory review procedures and submissions requirements as more traditional pharmaceutical agents. In addition, the FDA often asks for specific information on the unique aspects
Autor:
L E, Spitler, M, del Rio, A, Khentigan, N I, Wedel, N A, Brophy, L L, Miller, W S, Harkonen, L L, Rosendorf, H M, Lee, R P, Mischak
Publikováno v:
Cancer research. 47(6)
We conducted a trial of a murine monoclonal antimelanoma antibody-ricin A chain immunotoxin (XOMAZYME-MEL) in 22 patients with metastatic malignant melanoma. The dose of immunotoxin administered ranged from 0.01 mg/kg daily for 5 days to 1 mg/kg dail